Chicago, Illinois 60612

  • Prostate Cancer


RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development of cancer. The use of lycopene may be an effective way to prevent prostate cancer. PURPOSE: Phase I trial to study the effectiveness of lycopene in preventing prostate cancer.

Study summary:

OBJECTIVES: - Determine any dose limiting toxicities and the maximum tolerated dose of lycopene administered orally as a food based delivery system in healthy male subjects 18-45 years of age for the chemoprevention of prostate cancer. - Determine the pharmacokinetics of this regimen in this population. - Determine the dose range of this regimen to be used in the 3 month multiple dose study, based on the toxicity, pharmacokinetics and feasibility resulting from the present study in this population. OUTLINE: This is a dose-escalation study. Patients receive a single dose of oral lycopene in a mixture of tomato paste, water, and olive oil over 15 minutes on day 1. Patients are asked to maintain a diet that contains negligible carotinoid for 28 days. Cohorts of 5 patients receive escalating doses of lycopene until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 5 patients experience dose limiting toxicities. Patients are followed weekly for 4 weeks. PROJECTED ACCRUAL: A total of 5-25 patients will be accrued for this study.


DISEASE CHARACTERISTICS: - Normal healthy males judged to be in good medical condition based on history and physical exam confirming the absence of chronic medical conditions - Baseline serum lycopene less than 600 nM PATIENT CHARACTERISTICS: Age: - 18 to 45 Performance status: - Karnofsky 100% Life expectancy: - Not specified Hematopoietic: - Hematologic function normal Hepatic: - Liver function normal - No hepatic disease Renal: - Kidney function normal - No renal disease Cardiovascular: - No hypertension requiring medication - No cardiovascular disease - Normal EKG Other: - No evidence of a psychiatric disorder - Must be within 15% of ideal body weight based on standard weight tables - No history of smoking within the past 3 months - At least 72 hours since prior alcohol consumption and no history of alcohol abuse - No history of gastrointestinal malabsorption or any other condition that could affect drug absorption - No allergy to tomato based products - No active malignancy at any site - No illness that would pose a threat or additional risk (e.g., thyroid disease, diabetes mellitus) PRIOR CONCURRENT THERAPY: Biologic therapy: - Not specified Chemotherapy: - Not specified Endocrine therapy: - Not specified Radiotherapy: - Not specified Surgery: - Not specified Other: - At least 14 days since prior prescription drugs - No concurrent regular prescription medications - At least 30 days since other prior experimental drugs - No concurrent participation in any other experimental trial



Primary Contact:

Study Chair
Keith A. Rodvold
University of Illinois

Backup Contact:


Location Contact:

Chicago, Illinois 60612
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source:

Date Processed: June 24, 2021

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on The form below is not enabled.